Literature DB >> 17638886

ERM/ETV5 up-regulation plays a role during myometrial infiltration through matrix metalloproteinase-2 activation in endometrial cancer.

Marta Monge1, Eva Colas, Andreas Doll, Marta Gonzalez, Antonio Gil-Moreno, Jesus Planaguma, Maite Quiles, Maria Antonia Arbos, Angel Garcia, Josep Castellvi, Marta Llaurado, Marina Rigau, Hafid Alazzouzi, Jordi Xercavins, Francesc Alameda, Jaume Reventos, Miguel Abal.   

Abstract

We have described recently the Ets family transcription factor, ERM/ETV5, specifically up-regulated in endometrioid endometrial carcinoma (EEC) and associated with myometrial infiltration. Ets family members have been correlated to tumor progression by up-regulating the expression of matrix-degrading proteases. In the present study, we investigated the possibility that in EEC, ERM/ETV5 may act by inducing the expression of genes involved in extracellular matrix remodeling. Unraveling the molecular events associated with the initiation of tumor invasion would represent an obvious improvement for EEC patients. The overexpression of ERM/ETV5 induced scattering in the endometrial cancer cell line Hec-1A, correlating to increased matrix metalloproteinase-2 (MMP-2) gelatinase activity. Both chromatin immunoprecipitation and reversion experiments with RNA interference and specific MMP-2 inhibitor showed a functional link between ERM/ETV5 overexpression and MMP-2 activation. The increased MMP-2 activity associated with overexpressed ERM/ETV5 in a mouse model conferred invasive capacity to endometrial tumors. Orthotopically implanted overexpressing ERM/ETV5 tumors presented a more aggressive and infiltrative pattern of myometrial invasion. Finally, the specific localization of ERM/ETV5 and MMP-2 at the invasive front of myometrial infiltrating human endometrial carcinomas further reinforced the hypothesis of a role for ERM/ETV5 in the early steps of endometrial dissemination. Taken together, these results lead us to propose that in EEC, ERM/ETV5 acts through MMP-2 gelatinolytic activity to confer invasive capabilities, associated with an initial switch to myometrial infiltration. They also postulate ERM/ETV5 as a valuable marker for patient stratification and a transcription pathway that should be evaluated for therapies specifically targeting the initial steps of EEC dissemination.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17638886     DOI: 10.1158/0008-5472.CAN-06-4487

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  ERM/ETV5 and RUNX1/AML1 expression in endometrioid adenocarcinomas of endometrium and association with neoplastic progression.

Authors:  Vanessa Paiva Leite de Sousa; Claudia Bessa Pereira Chaves; Janina Ferreira Loureiro Huguenin; Fábio Carvalho de Barros Moreira; Bruno Souza Bianchi de Reis; Leila Chimelli; Anke Bergmann; Tatiana de Almeida Simão; Luis Felipe Ribeiro Pinto
Journal:  Cancer Biol Ther       Date:  2014-04-22       Impact factor: 4.742

Review 2.  ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.

Authors:  Sangphil Oh; Sook Shin; Ralf Janknecht
Journal:  Biochim Biophys Acta       Date:  2012-03-08

3.  Kisspeptin regulation of human decidual stromal cells motility via FAK-Src intracellular tyrosine kinases.

Authors:  H-M Wu; H-Y Huang; Y-K Soong; P C K Leung; H-S Wang
Journal:  Hum Reprod       Date:  2019-07-08       Impact factor: 6.918

4.  Nidogen 1 and Nuclear Protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion.

Authors:  Núria Pedrola; Laura Devis; Marta Llauradó; Irene Campoy; Elena Martinez-Garcia; Marta Garcia; Laura Muinelo-Romay; Lorena Alonso-Alconada; Miguel Abal; Francesc Alameda; Gemma Mancebo; Ramon Carreras; Josep Castellví; Sílvia Cabrera; Antonio Gil-Moreno; Xavier Matias-Guiu; Juan L Iovanna; Eva Colas; Jaume Reventós; Anna Ruiz
Journal:  Clin Exp Metastasis       Date:  2015-04-30       Impact factor: 5.150

5.  The role of Pea3 group transcription factors in esophageal squamous cell carcinoma.

Authors:  Hiu-Fung Yuen; Cian M McCrudden; Ka-Kui Chan; Yuen-Piu Chan; Michelle Lok-Yee Wong; Kelvin Yuen-Kwong Chan; Ui-Soon Khoo; Simon Law; Gopesh Srivastava; Terence R Lappin; Kwok-Wah Chan; Mohamed El-Tanani
Journal:  Am J Pathol       Date:  2011-05-31       Impact factor: 4.307

Review 6.  New insights into the role of Runx1 in epithelial stem cell biology and pathology.

Authors:  Cornelia Johanna Franziska Scheitz; Tudorita Tumbar
Journal:  J Cell Biochem       Date:  2013-05       Impact factor: 4.429

Review 7.  The EMT signaling pathways in endometrial carcinoma.

Authors:  Eva Colas; Nuria Pedrola; Laura Devis; Tugçe Ertekin; Irene Campoy; Elena Martínez; Marta Llauradó; Marina Rigau; Mireia Olivan; Marta Garcia; Silvia Cabrera; Antonio Gil-Moreno; Jordi Xercavins; Josep Castellvi; Angel Garcia; Santiago Ramon y Cajal; Gema Moreno-Bueno; Xavier Dolcet; Francesc Alameda; Jose Palacios; Jaime Prat; Andreas Doll; Xavier Matias-Guiu; Miguel Abal; Jaume Reventos
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

8.  PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cells.

Authors:  Zoulika Kherrouche; Didier Monte; Elisabeth Werkmeister; Luc Stoven; Yvan De Launoit; Alexis B Cortot; David Tulasne; Anne Chotteau-Lelievre
Journal:  Mol Oncol       Date:  2015-07-15       Impact factor: 6.603

9.  Loss of Etv5 decreases proliferation and RET levels in neonatal mouse testicular germ cells and causes an abnormal first wave of spermatogenesis.

Authors:  Gaurav Tyagi; Kay Carnes; Carla Morrow; Natalia V Kostereva; Gail C Ekman; Daryl D Meling; Chris Hostetler; Michael Griswold; Kenneth M Murphy; Rex A Hess; Marie-Claude Hofmann; Paul S Cooke
Journal:  Biol Reprod       Date:  2009-04-15       Impact factor: 4.285

10.  ETV4 and ETV5 drive synovial sarcoma through cell cycle and DUX4 embryonic pathway control.

Authors:  Joanna DeSalvo; Yuguang Ban; Luyuan Li; Xiaodian Sun; Zhijie Jiang; Darcy A Kerr; Mahsa Khanlari; Maria Boulina; Mario R Capecchi; Juha M Partanen; Lin Chen; Tadashi Kondo; David M Ornitz; Jonathan C Trent; Josiane E Eid
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.